Pascal Minini

1.6k total citations
39 papers, 1.1k citations indexed

About

Pascal Minini is a scholar working on Surgery, Physiology and Economics and Econometrics. According to data from OpenAlex, Pascal Minini has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 8 papers in Physiology and 8 papers in Economics and Econometrics. Recurrent topics in Pascal Minini's work include Lipoproteins and Cardiovascular Health (12 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Lysosomal Storage Disorders Research (6 papers). Pascal Minini is often cited by papers focused on Lipoproteins and Cardiovascular Health (12 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Lysosomal Storage Disorders Research (6 papers). Pascal Minini collaborates with scholars based in France, United States and United Kingdom. Pascal Minini's co-authors include Frédéric Roche, Jean‐Michel Gaspoz, Vincent Pichot, Anestis Antoniadis, Jean Barthélemy, F. Costes, Jean‐René Lacour, Jean-Ren� Lacour, Thierry Busso and Daniel Gaudet and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Brain.

In The Last Decade

Pascal Minini

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Minini France	16	427	407	264	172	162	39	1.1k
A. Hage United States	18	1.1k 2.6×	1.0k 2.6×	147 0.6×	263 1.5×	346 2.1×	42	2.3k
Heinz Theres Germany	20	208 0.5×	853 2.1×	158 0.6×	124 0.7×	48 0.3×	84	1.6k
Begoña Benito Spain	26	213 0.5×	2.5k 6.2×	181 0.7×	37 0.2×	111 0.7×	101	2.9k
James B. Strait United States	15	138 0.3×	984 2.4×	198 0.8×	51 0.3×	65 0.4×	21	1.5k
Candela Díaz-Cañestro Canada	17	112 0.3×	517 1.3×	275 1.0×	26 0.2×	332 2.0×	49	1.4k
Giuseppe Coppola Italy	23	433 1.0×	1.0k 2.5×	133 0.5×	49 0.3×	25 0.2×	82	1.9k
Jacob B. Blumenthal United States	15	92 0.2×	118 0.3×	379 1.4×	78 0.5×	100 0.6×	36	932
Benno Nafz Germany	21	124 0.3×	532 1.3×	295 1.1×	83 0.5×	29 0.2×	38	1.0k
Jerzy Stańczyk Poland	13	151 0.4×	275 0.7×	79 0.3×	49 0.3×	43 0.3×	73	749

Countries citing papers authored by Pascal Minini

Since Specialization

Citations

This map shows the geographic impact of Pascal Minini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Minini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Minini more than expected).

Fields of papers citing papers by Pascal Minini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Minini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Minini. The network helps show where Pascal Minini may publish in the future.

Co-authorship network of co-authors of Pascal Minini

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Minini. A scholar is included among the top collaborators of Pascal Minini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Minini. Pascal Minini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Minini, Pascal, Florian Eichler, Christopher D. Stephen, et al.. (2024). Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses. Molecular Genetics and Metabolism. 142(3). 108512–108512. 1 indexed citations

Giladi, Nir, Roy N. Alcalay, Gary Cutter, et al.. (2023). Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 22(8). 661–671. 38 indexed citations

Zhang, Qi, et al.. (2023). A Case Study of 2-Stage Seamless Adaptive Sample Size Re-Estimation Design with Efficacy Interim Analysis When Slope Is the Primary Endpoint. Statistics in Biopharmaceutical Research. 16(2). 218–228. 1 indexed citations

Gansevoort, Ronald T., Ali Hariri, Pascal Minini, et al.. (2022). Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. American Journal of Kidney Diseases. 81(5). 517–527.e1. 12 indexed citations

Perrone, Ronald D., Ali Hariri, Pascal Minini, et al.. (2022). The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD. Kidney Medicine. 4(10). 100538–100538. 7 indexed citations

Peterschmitt, Michel, Thomas Gasser, Stuart Isaacson, et al.. (2019). Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson disease patients with a GBA mutation. Molecular Genetics and Metabolism. 126(2). S117–S117. 15 indexed citations

Puga, Ana Cristina, Alaa Hamed, Pascal Minini, et al.. (2018). Functional performance in late-onset GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases), longitudinal data over 3 consecutive years. Molecular Genetics and Metabolism. 123(2). S122–S122. 1 indexed citations

Colin, Pierre, Maud Delattre, Pascal Minini, & Sandrine Micallef. (2017). An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials. Journal of Biopharmaceutical Statistics. 27(6). 1054–1072. 3 indexed citations

Ray, Kausik K., Henry N. Ginsberg, Michael H. Davidson, et al.. (2016). Abstract 18484: Modest Potential Association Between Reductions in Lipoprotein(a) and Major Adverse Cardiovascular Events in the Phase 3 Trials of Alirocumab versus Control. Circulation. 3 indexed citations

10.

Cannon, Christopher P., Henry N. Ginsberg, Kausik K. Ray, et al.. (2016). RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL. Journal of the American College of Cardiology. 67(13). 1867–1867. 1 indexed citations

11.

Kastelein, John J.P., G. Kees Hovingh, Gisle Langslet, et al.. (2016). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of clinical lipidology. 11(1). 195–203.e4. 56 indexed citations

12.

Gaudet, Daniel, Gerald F. Watts, Jennifer G. Robinson, et al.. (2016). Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program). The American Journal of Cardiology. 119(1). 40–46. 105 indexed citations

13.

Ray, Kausik K., Henry N. Ginsberg, Michael H. Davidson, et al.. (2016). Reductions in Atherogenic Lipids and Major Cardiovascular Events. Circulation. 134(24). 1931–1943. 96 indexed citations

14.

Kastelein, John J.P., Dean J. Kereiakes, Christopher P. Cannon, et al.. (2016). Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia. Coronary Artery Disease. 28(3). 190–197. 21 indexed citations

15.

Lane, Deirdre A., Pieter W. Kamphuisen, Pascal Minini, Harry R. Büller, & Gregory Y.H. Lip. (2011). Bleeding Risk in Patients With Atrial Fibrillation. CHEST Journal. 140(1). 146–155. 26 indexed citations

16.

Lane, Deirdre A., Pieter W. Kamphuisen, Pascal Minini, Harry R. Büller, & Gregory Y.H. Lip. (2010). Safety and efficacy of anticoagulation for secondary stroke prevention in atrial fibrillation patients: The AMADEUS trial. University of Groningen research database (University of Groningen / Centre for Information Technology). 2 indexed citations

17.

Wong, Florence, Pere Ginès, Frederik Nevens, et al.. (2009). Double-blind, placebo-controlled study of satavaptan in the management of recurrent ascites: the spare-1 study. Hepatology. 50(4). 1 indexed citations

18.

Minini, Pascal & M. Chavance. (2004). Sensitivity analysis of longitudinal binary data with non-monotone missing values. Biostatistics. 5(4). 531–544. 17 indexed citations

19.

Casset‐Semanaz, Florence, et al.. (2004). Du bon usage des tests dans les essays cliniques. médecine/sciences. 20(2). 231–235. 4 indexed citations

20.

Liese, Johannes G., S Stojanov, Pascal Minini, et al.. (2001). Large scale safety study of a liquid hexavalent vaccine (D-T-acP–IPV–PRP∼T–HBs) administered at 2, 4, 6 and 12–14 months of age. Vaccine. 20(3-4). 448–454. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact